| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1999;117:736-743
© 1999 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the Thoracic Oncology Program, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC.
Supported by National Cancer Institute grant R29 CA73980.
Read at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
Received for publication July 15, 1998. revisions requested Sept 8, 1998. revisions received Nov 13, 1998. Accepted for publication Dec 10, 1998. Address for reprints: Thomas A. D'Amico, MD, Duke University Medical Center, Box 3496, Durham, NC 27707.
Objective: The standard treatment of patients with stage I non–small cell lung cancer is resection of the primary tumor; however, the recurrence rate is 28% to 45%. This study evaluates a panel of molecular markers in a large population of patients with stage I non–small cell lung cancer to determine the prognostic value of each marker and to create a biologic risk model.
Methods: Pathologic specimens were collected from 408 consecutive patients after complete resection for stage I non–small cell lung cancer at a single institution, with follow-up of at least 5 years. A panel of 10 molecular markers was chosen for immunohistochemical analysis of the primary tumor on the basis of differing oncogenic mechanisms. Local tumor expansion requires growth regulating proteins (epidermal growth factor receptor, the protooncogene erb-b2); apoptosis proteins (p53, bcl-2); and cell cycle regulating proteins (retinoblastoma recessive oncogene, KI-67). Local tumor invasion requires angiogenesis (factor viii). The development of distant metastases involves the expression of adhesion proteins (CD-44, sialyl-Tn, blood group A). Cox proportional hazards regression analysis was used to construct an independent risk model for cancer recurrence and death.
Results: Multivariable analysis demonstrated significantly elevated risk for the following molecular markers: p53 (hazard ratio, 1.68; P = .004); factor viii (hazard ratio, 1.47 P = .033); erb-b2 (hazard ratio, 1.43; P = .044); CD-44 (hazard ratio, 1.40; P = .050); and retinoblastoma recessive oncogene (hazard ratio, 0.747; P = .084).
Conclusions: Five molecular markers were associated with the risk of recurrence and death, representing independent metastatic pathways: apoptosis (p53), angiogenesis (factor viii), growth regulation (erb-b2), adhesion (CD-44), and cell cycle regulation (retinoblastoma recessive oncogene). This study demonstrates the validity of this molecular biologic risk model in patients with stage I non– small cell lung cancer.
This article has been cited by other articles:
|
|
 |
|
  C. E. Reed, A. Graham, R. S. Hoda, A. Khoor, E. Garrett-Mayer, M. B. Wallace, and M. Mitas A simple two-gene prognostic model for adenocarcinoma of the lung J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 627 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. D'Amico Molecular Biologic Staging of Lung Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): S737 - S742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suzuki, S. Ishikawa, H. Satoh, H. Ishikawa, M. Sakai, T. Yamamoto, M. Onizuka, and Y. Sakakibara Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 648 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gebitekin, A. S Bayram, B. Tunca, and S. A Balaban Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 35 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Satoh, R. Hoshi, Y. Ishikawa, T. Horai, S. Okumura, and K. Nakagawa Recurrence Patterns in Patients With Early Stage Non-Small Cell Lung Cancers Undergoing Positive Pleural Lavage Cytology Ann. Thorac. Surg., January 1, 2007; 83(1): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lim Invited commentary Ann. Thorac. Surg., January 1, 2007; 83(1): 202 - 203. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Potti, S. Mukherjee, R. Petersen, H. K. Dressman, A. Bild, J. Koontz, R. Kratzke, M. A. Watson, M. Kelley, G. S. Ginsburg, et al. A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer N. Engl. J. Med., August 10, 2006; 355(6): 570 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico, K. R. Brooks, M.-B. M. Joshi, D. Conlon, J. Herndon II, R. P. Petersen, and D. H. Harpole Jr Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection Ann. Thorac. Surg., June 1, 2006; 81(6): 1982 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis Thorax, February 1, 2006; 61(2): 140 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dutu, S. Michiels, P. Fouret, F. Penault-Llorca, P. Validire, S. Benhamou, E. Taranchon, L. Morat, D. Grunenwald, T. Le Chevalier, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers Ann. Onc., December 1, 2005; 16(12): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer Chest, July 1, 2005; 128(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Berghmans, A. P. Meert, B. Martin, V. Ninane, and J. P. Sculier Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Eur. Respir. J., February 1, 2005; 25(2): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, J.-C. Soria, X. Tang, X.-C. Xu, L. Wang, L. Mao, R. Lotan, B. Kemp, B. N. Bekele, L. Feng, et al. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers J. Clin. Oncol., November 15, 2004; 22(22): 4575 - 4583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico Value of intraoperative pleural lavage in staging non-small cell lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 947 - 948. [Full Text] [PDF]
|
|
|
|
|
|
A. Sayar, A. Turna, O. Solak, A. Kilicgun, N. Urer, and A. Gurses Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker Ann. Thorac. Surg., February 1, 2004; 77(2): 421 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Wu, C.-F. J. Lin, W.-H. Hsu, B.-S. Huang, M.-H. Huang, and L.-S. Wang Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control Eur. J. Cardiothorac. Surg., December 1, 2003; 24(6): 994 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis J. Clin. Oncol., October 15, 2003; 21(20): 3798 - 3807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. DiPerna, R. D. Bart, E. M. Sievers, Y. Ma, V. A. Starnes, and R. M. Bremner Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1129 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gawrychowski, B. Lackowska, and A. Gabriel Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC) - relation to DNA ploidy Eur. J. Cardiothorac. Surg., June 1, 2003; 23(6): 870 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Poleri, J. L. Morero, B. Nieva, M. F. Vazquez, C. Rodriguez, E. de Titto, and M. Rosenberg Risk of Recurrence in Patients With Surgically Resected Stage I Non-small Cell Lung Carcinoma: Histopathologic and Immunohistochemical Analysis Chest, June 1, 2003; 123(6): 1858 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types J. Clin. Oncol., November 1, 2002; 20(21): 4292 - 4302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur. Respir. J., October 1, 2002; 20(4): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-S. Lai, J.-S. Wang, H.-K. Hsu, H.-C. Chang, C.-H. Lin, and M.-H. Lin Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 393 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kara, E. Dikmen, D. Kilic, S. Dizbay Sak, D. Orhan, S. K. Kose, and S. Kavukcu Prognostic implications of microscopic proximal bronchial extension in non-small cell lung cancer Ann. Thorac. Surg., August 1, 2002; 74(2): 348 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico Molecular biologic substaging of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 409 - 410. [Full Text] [PDF]
|
|
|
|
|
|
W.-W. Lai, F.-F. Chen, M.-H. Wu, N.-H. Chow, W.-C. Su, M.-C. Ma, P.-F. Su, H. Chen, M.-Y. Lin, and Y.-L. Tseng Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Ann. Thorac. Surg., December 1, 2001; 72(6): 1868 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico, T. A. Aloia, M.-B. H. Moore, D. H. Conlon, J. E. Herndon II, M. S. Kinch, and D. H. Harpole Jr Predicting the sites of metastases from lung cancer using molecular biologic markers Ann. Thorac. Surg., October 1, 2001; 72(4): 1144 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Aloia, D. H. Harpole Jr, C. E. Reed, C. Allegra, M.-B. H. Moore, J. E. Herndon II, and T. A. D'Amico Tumor marker expression is predictive of survival in patients with esophageal cancer Ann. Thorac. Surg., September 1, 2001; 72(3): 859 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Maguire, L. B. Marks, G. S. Sibley, J. E. Herndon II, R. W. Clough, K. L. Light, M. L. Hernando, P. A. Antoine, and M. S. Anscher 73.6 Gy and Beyond: Hyperfractionated, Accelerated Radiotherapy for Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2001; 19(3): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. d. O. Carvalho, L. Antonangelo, F. D. C. Bernardi, L. E. V. Leao, O. R. Rodrigues, and V. L. Capelozzi Useful Prognostic Panel Markers to Express the Biological Tumor Status in Resected Lung Adenocarcinomas Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 478 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hommura, H. Dosaka-Akita, T. Mishina, M. Nishi, T. Kojima, H. Hiroumi, S. Ogura, M. Shimizu, H. Katoh, and Y. Kawakami Prognostic Significance of p27KIP1 Protein and Ki-67 Growth Fraction in Non-small Cell Lung Cancers Clin. Cancer Res., October 1, 2000; 6(10): 4073 - 4081. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. D’Amico, T. A. Aloia, M.-B. H. Moore, J. E. Herndon II, K. R. Brooks, C. L. Lau, and D. H. Harpole Jr Molecular biologic substaging of stage I lung cancer according to gender and histology Ann. Thorac. Surg., March 1, 2000; 69(3): 882 - 886. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
